Availability of miltefosine for the treatment of kala-azar in India

Bulletin of the World Health Organization

Volumn 83, Issue 5, 2005, Pages 394-395

  Sundar, Shyam ^a   Murray, Henry W ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; MILTEFOSINE;

DISEASE CONTROL; DRUG PRESCRIBING;

DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; FOLLOW UP; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INDIA; LEISHMANIASIS; PRACTICE GUIDELINE; PRESCRIPTION; RELAPSE; REVIEW; TREATMENT OUTCOME;

ANTIPROTOZOAL AGENTS; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; POVERTY;

ASIA; EASTERN HEMISPHERE; EURASIA; INDIA; SOUTH ASIA; WORLD;

NASO HEXACANTHUS;

EID: 18944370727     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3.
2. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 2002;347:1739-46.
3. Thakur CP. Socio-economics of visceral leishmaniasis in Bihar (India). Transactions of the Royal Society of Tropical Medicine and Hygiene 2000;94:156-7.
4. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clinical Infectious Diseases 2000;31:1104-6.
5. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infectious Diseases 2002;2:494-501.